Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDR404 in MAGE-A4 Expressing Advanced Solid Tumors
NCT06402201Phase 1Recruiting
- Sponsor
- CDR-Life
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Fragments, Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of CDR404 in solid tumor, sponsored by CDR-Life. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 90 days and 1 more. Started May 2024; status: recruiting.
02
Drugs
CDR404
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06402201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402201.